Front. Pharmacol. Frontiers in Pharmacology Front. Pharmacol. 1663-9812 Frontiers Media S.A. 1656591 10.3389/fphar.2025.1656591 Pharmacology Correction Correction: 1,8-Cineole inhibits platelet-leukocyte aggregate formation by reducing P-selectin expression Petry et al. 10.3389/fphar.2025.1656591 Petry Julie Mai Han Shoykhet Maria Bashiri Dezfouli Ali Wollenberg Barbara * Department of Otorhinolaryngology, Head and Neck Surgery, School of Medicine and Health, TUM University Hospital, Technical University of Munich, Munich, Germany

Approved by: Frontiers Editorial Office, Frontiers Media SA, Switzerland

 *Correspondence: Barbara Wollenberg, barbara.wollenberg@tum.de 10 07 2025 2025 16 1656591 30 06 2025 01 07 2025 Copyright © 2025 Petry, Mai, Shoykhet, Bashiri Dezfouli and Wollenberg. 2025 Petry, Mai, Shoykhet, Bashiri Dezfouli and Wollenberg

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

 A Correction on 1,8-Cineole inhibits platelet-leukocyte aggregate formation by reducing P-selectin expression by Petry J, Mai H, Shoykhet M, Bashiri Dezfouli A and Wollenberg B (2025). Front. Pharmacol. 16:1546157. doi: 10.3389/fphar.2025.1546157 1,8-cineole platelets platelet-leukocyte aggregates anti-platelet drugs head and neck squamous cell carcinoma section-at-acceptance Ethnopharmacology

File Supplementary file 2 was erroneously published with the original version of this paper. The file has now been removed.

Supplementary file 2 was erroneously cited in the manuscript as “Supplementary Material.” With the removal of Supplementary file 2, the corresponding in-text citation has also been deleted.

A correction has been made to the section 2 Materials and methods, 2.1 Chemicals and drugs, Paragraph 1. The sentence previously stated:

“1,8-cineole (CNL-1976®) was provided by Klosterfrau Healthcare Group, Cassella-med GmbH & Co. KG (Cologne, Germany) with a purity of 99.5% (Supplementary Material) and stock solutions were prepared by solving native extract in ethanol (5 M) followed by a final dilution in Tyrode buffer (137 mM NaCl, 2 mM KCl, 12 mM NaHCO3, 0.3 mM NaH2PO4, 1 mM MgCl2, 5 mM HEPES, 5.5 mM glucose, 0.5% bovine serum albumin).”

This has been updated to:

“1,8-cineole (CNL-1976®) was provided by Klosterfrau Healthcare Group, Cassella-med GmbH & Co. KG (Cologne, Germany) with a purity of 99.5% and stock solutions were prepared by solving native extract in ethanol (5 M) followed by a final dilution in Tyrode buffer (137 mM NaCl, 2 mM KCl, 12 mM NaHCO3, 0.3 mM NaH2PO4, 1 mM MgCl2, 5 mM HEPES, 5.5 mM glucose, 0.5% bovine serum albumin).”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.